newsfilter
← Latest News
GlobeNewswire·

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy